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Although cell–cell fusion assays are useful surrogate methods for studying virus fusion, differences between cell–cell and virus–cell fusion
exist. To examine paramyxovirus fusion in real time, we labeled viruses with fluorescent lipid probes and monitored virus–cell fusion by
fluorimetry. Two parainfluenza virus 5 (PIV5) isolates (W3A and SER) and PIV5 containing mutations within the fusion protein (F) were studied.
Fusion was specific and temperature-dependent. Compared to many low pH-dependent viruses, the kinetics of PIV5 fusion was slow, approaching
completion within several minutes. As predicted from cell–cell fusion assays, virus containing an F protein with an extended cytoplasmic tail
(rSV5 F551) had reduced fusion compared to wild-type virus (W3A). In contrast, virus–cell fusion for SER occurred at near wild-type levels,
despite the fact that this isolate exhibits a severely reduced cell–cell fusion phenotype. These results support the notion that virus–cell and cell–
cell fusion have significant differences.
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The entry of enveloped viruses into cells requires fusion of
the viral lipid bilayer with the membrane of a host cell. For the
paramyxovirus parainfluenza virus 5 (PIV5, formerly known as
SV5), fusion requires the concerted action of two glycoproteins;
the receptor binding protein hemagglutinin–neuraminidase
(HN) and the fusion glycoprotein (F). Like other class I viral
fusion glycoproteins, F protein is expressed as a metastable
protein that is triggered to undergo a protein refolding event that
induces membrane fusion. Our understanding of the mechanism
of paramyxovirus membrane fusion has increased greatly with
the determination of the pre-fusion and post-fusion F atomic
structures (Yin et al., 2005, 2006). The mechanism of triggering
differs for various class I fusion proteins (Jardetzky and Lamb,
2004; Lamb et al., 2006). Whereas influenza virus hemagglu-
tinin (HA) is triggered by the low pH environment found in the
endosomal lumen, paramyxovirus F protein is triggered at a
neutral pH by HN binding to receptors at the cell surface (Lamb⁎ Corresponding author. BMBCB, Northwestern University, 2205 Tech Drive,
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doi:10.1016/j.virol.2006.07.021and Kolakofsky, 2001). Although PIV5 F can mediate fusion of
transfected cells in the absence of HN, this fusion is enhanced
by the addition of HN (Russell et al., 2001) and mutations
within PIV5 F can impart HN dependence to the fusion process
(Ito et al., 1997; Paterson et al., 2000). In the context of virus,
HN is always present with the F protein and thus HN-
independent fusion does not occur during virus–cell fusion.
Paramyxovirus F proteins are synthesized as biologically
inactive precursors (F0) that must be cleaved prior to fusion.
Cleavage of F0 results in the generation of the N-terminus of the
F1 subunit that contains the hydrophobic fusion peptide (Lamb
and Kolakofsky, 2001). After triggering by HN, the fusion
peptide intercalates into a target membrane and the F protein
undergoes a refolding process that drives membrane merger.
Both the fusion peptide and transmembrane regions of the F
protein are flanked by heptad repeat regions (HRA and HRB
respectively), and these heptad repeats form a stable six-helix
bundle upon fusion (Baker et al., 1999; Joshi et al., 1998).
Peptides synthesized to correspond to HRA and HRB sequences
can inhibit fusion by trapping F at intermediate states and
preventing completion of the conformational change required
for fusion (Russell et al., 2001).
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assays, that mutations within the PIV5 F protein can alter the
energy threshold required to trigger refolding into a fusogenic
form. Some mutations, such as extending the length of the
cytoplasmic tail, increase the energy threshold required to
trigger fusion and result in reduced cell–cell fusion (Seth et al.,
2003; Waning et al., 2004). Other mutations, such as S443P,
L447F, and L449F, reduce the energy threshold required to
trigger fusion and result in a hyperfusogenic phenotype
(Paterson et al., 2000; Russell et al., 2003).
A variety of cell–cell fusion assays have been used to study
fusion mediated by the paramyxovirus F and HN proteins,
including syncytium formation assays, reporter assays including
a quantitative luciferase assay, and a fluorescent dye transfer
assay (Paterson et al., 2000; Russell et al., 2001). Each of these
assays operates on a different time scale, and together they
provide the basis for our understanding of the fusionmechanism.
While cell–cell fusion assays are useful surrogate methods for
studying virus fusion, differences between cell–cell fusion and
virus–cell fusion exist, and hence the need for direct assays of
virus–cell fusion. For example, although BHK and HeLa cells
are permissive to PIV5 infection, only BHK cells form syncytia.
The lack of syncytia in HeLa cells is not due to an inherent
property of these cells, as infection with another paramyxovirus,
human parainfluenza virus 3 (hPIV3) does result in syncytium
formation (S.A.C., unpublished observations).
Previous analyses of Sendai virus–cell fusion or virus–
liposome fusion have yielded conflicting data. In one case,
fusion occurred over a 16 h time period (Wharton et al., 2000),
whereas in other cases fusion occurred over 10 min (Hoekstra
and Klappe, 1986) or 30 min (Ludwig et al., 2003). These
differences in kinetics may result in part from the different
techniques and fluorescent probes used.
To compare virus–cell fusion and cell–cell fusion, we
employed two virus–cell fusion assays using fluorescent lipid
probes. By labeling virus with probes that exhibit concentra-
tion-dependent fluorescent changes, we were able to monitor
virus–cell fusion in real time for two PIV5 isolates (W3A and
SER) and PIV5 containing F mutations. Fusion was specific
and approached completion within several minutes. As pre-
dicted from cell–cell fusion assays, the kinetic rate and the final
extent of virus–cell fusion for virus containing an F protein
with an extended cytoplasmic tail (rSV5 F551) were reduced
compared to virus containing a wild-type (wt) F protein (W3A).
In contrast, virus–cell fusion for the PIV5 isolate SER occurred
at near wt levels, despite the fact that the PIV5 isolate SER
exhibits a severely reduced cell–cell fusion phenotype
(Bissonnette et al., 2006; Seth et al., 2003; Tong et al., 2002).
This finding supports the notion that virus–cell and cell–cell
fusion have significant differences.
Results
Pyrene-labeled W3A virus fusion with BHK cells.
To study fusion of PIV5 with cells, we adapted a method used
previously for studying fusion of enveloped viruses, e.g.vesicular stomatitis virus and Semliki forest virus (Pal et al.,
1988; Stegmann et al., 1993) in which pyrene is incorporated
biosynthetically into virus. At high concentration, pyrene forms
excimers that fluoresce at 475 nm.When present in a monomeric
state, pyrene fluorescence shifts to 396 nm. Fusion of labeled
virusmembranes with target cell membranes can bemeasured by
monitoring pyrene monomer and/or excimer fluorescence as
fusion progresses and the probe is diluted into the target
membrane. As pyrene is incorporated into both leaflets of the
viral lipid bilayer, both hemi-fusion and complete fusion of the
virus will contribute to the fluorescence signal.
Pyrene was incorporated biosynthetically into PIV5 W3A
virus, and virus was purified. Pyrene-labeled virions were bound
to BHK cells on ice, and virus–cell fusion was examined by
injecting the virus–cell mixtures into 37 °C PBS and observing
changes in emission spectra over time (Fig. 1A). As expected,
monomer fluorescence increased and excimer fluorescence
decreased over time. To examine fusion kinetics, the increase
in monomer fluorescence was monitored over 1000 s. To
determine the total amount of pyrene present in each sample,
Triton X-100 was injected at a final concentration of 1% to
disrupt the membranes and fully dilute the probe.
PIV5 W3A virus fusion with BHK cells occurred relatively
slowly compared to reports describing low pH-triggered virus
fusion of tick-borne encephalitis virus, Sindbis virus, and
Semliki forest virus which occurs in seconds (Corver et al.,
2000; Smit et al., 1999; Waarts et al., 2002). For PIV5 W3A,
fluorescence was still increasing after 15 min at 37 °C (Fig. 1B)
and did not reach a plateau even after 30 min (data not shown).
However, the specificity of fusion was confirmed by inhibiting
fusion with addition of IgG of a neutralizing MAb specific for
PIV5 F protein (F1a). Fusion was not blocked by addition of a
control MAb IgG (14C2) or F1a IgG denatured by boiling.
Fusion was also inhibited by addition of C1 peptide (corre-
sponding to the amino sequence of HRB), and this inhibition
occurred in a dose-dependent manner (Fig. 1C). The C1 peptide
prevents fusion by binding to F protein and trapping it in an
intermediate conformation, most likely at the pre-hairpin inter-
mediate (Russell et al., 2001).
The temperature dependence of W3A fusion was examined
(Fig. 1D). Whereas very little fusion occurred at 25 °C,
increasing the temperature from 37 °C to 45 °C or 53 °C in-
creased both the rate and extent of fusion. Conversely, fusion
could be prevented by inactivation of W3A virus with high
temperatures (Fig. 1E). Fusion was unaffected by pre-treating
the virus for 10 min at temperatures up to 53 °C prior to binding
cells. However, pre-treating the virus at 65 °C or 75 °C com-
pletely inactivated the virus and prevented fusion.
R18-labeled W3A virus fusion with BHK cells
As the optimal conditions for labeling virus with pyrene at
excimer concentrations required a high MOI infection and
incubation for a maximum of 48 h, the resulting purified virus
preparations gave relatively low virus yields (reduced approxi-
mately 10-fold compared to standard conditions). In addition,
although it might be expected that the monomer fluorescence
Fig. 1. Fusion of pyrene-labeled W3A virus with BHK cells. (A) Purified pyrene-labeled W3Awas incubated with BHK cells on ice for 30 min, and samples were
injected into a cuvette containing 3 mL of PBS pre-warmed to 37 °C. Fluorescence emission spectra were recorded at the initial injection of the sample and after 11 min
at 37 °C. (B) Samples were treated as in panel A, and monomeric pyrene formation was monitored continuously at 396 nm for 1000 s. Maximum emission at 396 nm
was determined by the addition of Triton X-100 to a final concentration of 1%. Data are expressed as a percentage of maximum emission with background (signal at
time zero) subtracted. Pyrene-labeled W3A virions were treated with MAb IgGs prior to binding to cells. F1a is a neutralizing MAb specific for F, and 14C2 is an
irrelevant MAb specific for the influenza virus M2 protein. As a control, F1a IgG was boiled prior to binding virus. (C) Pyrene-labeled W3A virions were incubated
with the indicated concentrations of C1 peptide prior to binding to BHK cells. Fusion was monitored as in panel B. The initial peptide concentrations listed were
diluted 30-fold by injection of samples into 3 mL of PBS. (D) To examine temperature dependence, fusion was monitored as in panel B, except the PBS in the cuvette
was held at the indicated temperatures. (E) To determine the temperature of inactivation for W3Avirions, pyrene-labeled W3Avirions were incubated at the indicated
temperatures for 10 min prior to binding to BHK cells on ice. Fusion was monitored as in panel B.
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Triton X-100, we found that the monomer signal took approx-
imately 2 min to achieve a maximum. Thus, to confirm our real-
time fusion observations, virus–cell fusion was also monitored
using another fluorescent probe, octadecyl rhodamine B (R18).
R18 associates with membranes rapidly (Hoekstra et al.,
1984) and can be used to label intact biological membranes,
permitting the use of high titer virus stocks grown under
standard conditions. At high concentrations, R18 is self-
quenching and viral fusion can be measured by monitoring
R18 dequenching as fusion with a target membrane progresses.
Purified PIV5 W3Awas labeled with R18 and pelleted through
a sucrose cushion. After binding virus to BHK cells on ice,
virus–cell fusion was examined by injecting the virus–cell
mixtures into 37 °C PBS and monitoring R18 dequenching. For
each sample, Triton X-100 was injected after 1000 s to
determine a maximum level of R18 dequenching.
As found in the pyrene assay, fusion of R18-labeled W3A
(Fig. 2A) was relatively slow. The specificity of fusion was
demonstrated by inhibiting fusion with F1a IgG, but not with thecontrol MAb IgG 14C2. Neuraminidase treatment of BHK cells
completely prevented fusion. While previous studies raise
concerns about spontaneous transfer of R18 to target membranes
(Ohki et al., 1998), these concerns were alleviated in this study
by the lack of R18 transfer to neuraminidase-treated BHK cells
and the inhibition of fusion by the neutralizing MAb F1a.
As shown using the pyrene assay, W3A fusion was
temperature-dependent (Fig. 2B). While very little fusion
occurred at 25 °C, both the rate and extent of fusion increased
at higher temperatures. As the temperature was increased, the
fluorescence maximums achieved after the addition of Triton X-
100 decreased (data not shown). This temperature-related effect
on R18 was normalized by expressing the data as percentages of
these maximums.
R18-labeled W3A virus fusion with RBC ghosts
To investigate the slow kinetics of PIV5 W3A fusion, we
examined virus–cell fusion using RBC ghosts as another target
cell type. Purified PIV5W3Awas labeled with R18 and bound to
Fig. 2. Fusion of R18-labeled W3Avirus with BHK cells. (A) R18-labeledW3A
was bound to BHK cells on ice for 30 min. The samples were injected into a
cuvette containing 3 mL of PBS pre-warmed to 37 °C. Fluorescence
dequenching was monitored at 590 nm for 1000 s. Maximum emission at
590 nm was determined by the addition of Triton X-100 to a final concentration
of 1%. Data are expressed as a percentage of maximum emission with
background subtracted. As a negative control, BHK cells were treated with
neuraminidase to destroy the target cell receptor sialic acid. R18-W3Awas pre-
incubated on ice with MAb IgG specific for F (F1a) or influenza M2 (14C2). (B)
To examine the temperature dependence of R18-labeled W3A virus fusion,
fusion with BHK cells was monitored as in panel A, except the PBS in the
cuvette was held at the indicated temperatures.
Fig. 3. Fusion of R18-labeled W3A virus with RBC ghosts. (A) R18-labeled
W3A was bound to RBC ghosts on ice for 30 min. The samples were injected
into a cuvette containing 3 mL of PBS pre-warmed to 37 °C. Readings were
initiated 20 s prior to the sample injection, and fluorescence dequenching was
monitored at 590 nm for 200 s. Maximum emission at 590 nm was determined
by the addition of Triton X-100 to a final concentration of 1%. Data are
expressed as a percentage of maximum emission at 590 nm. As a negative
control, RBC ghosts were treated with neuraminidase to destroy the target cell
receptor sialic acid. R18-W3A virus was pre-incubated on ice with MAb IgG
specific for F (F1a) or influenza M2 (14C2). (B) For comparison, R18-labeled
influenza virus was treated as in panel A. To trigger the pH-dependent fusion of
influenza virus, the pH of the solution was lowered to 5 at 80 s. (C) To examine
temperature dependence, the virus–cell fusion assay was performed as in panel
A with the PBS in the cuvette held at the indicated temperatures during fusion.
Fusion with neuraminidase-treated RBC ghosts was monitored as a negative
control.
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and Triton X-100 was injected after 200 s to determine the
maximum levels of dequenching. Data were expressed as a
percentage of these maximums. Unlike in the previous assays,
the initial values were not subtracted because light scattering
upon injection of the 100 μg of RBC ghosts resulted in large
spikes in the readings (Fig. 3). These large spikes preclude an
estimation of the initial rate of fusion. For viruses that have low-
pH triggered fusion, virus and target membranes can be mixed at
37 °C prior to injection of acid pH and it is relatively simple to
measure the initial rates of fusion (Fig. 3B). However, for viruses
that fuse at neutral pH and where incubation at 37 °C is the
trigger for fusion, there is no alternative but to bind the virus to
the ghosts at 4 °C and to inject the virus–ghosts into pre-warmed
PBS in the fluorimeter. It is not possible to hold the labeled virus
bound to RBC ghosts at 4 °C in the fluorimeter cuvette and to
heat the sample instantaneously to precisely 37 °C at time zero.
PIV5 W3A virus fusion with RBC ghosts (Fig. 3A) was
relatively slow compared to influenza virus fusion induced afterlow pH treatment (Fig. 3B). However, PIV5 W3A fusion
progressed faster using this technique than compared to the
kinetics of fusion when using BHK cells (cf. Figs. 1B, 2A, and
Fig. 4. Fusion of PIV5 isolate SER and mutant PIV5 virus. (A) Diagram of
W3A, SER, and F551 F proteins, indicating mutated residues and elongated
cytoplasmic tails as compared to W3A F. (B) Purified virus preparations (10 μg
total protein) were analyzed by SDS-PAGE on a 10% acrylamide gel followed
by silver staining. (C) Fusion of R18-labeled W3A, SER, and rSV5 F551 with
BHK cells. Fusion was analyzed as in Fig. 2A. Fusion with neuraminidase-
treated BHK cells was monitored as a negative control. (D) Fusion of R18-
labeledW3A, SER, and rSV5 F551 with RBC ghosts. Fusion was analyzed as in
Fig. 3A.
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treatment inhibited fusion (Fig. 3A) and fusion was found to be
temperature-dependent (Fig. 3C).
The temperature of fusion inactivation was also examined
using this assay. As in the pyrene assay, viral fusion was
inactivated after pre-treatment at 65 °C for 10 min, whereas
fusion was not inactivated by pre-treatment at 53 °C (data not
shown).
Mutations in F glycoprotein affect virus–cell fusion
The R18 virus–cell fusion assay was used, with BHK cells or
RBC ghosts as target membranes, to compare the fusion of PIV5
W3A and another PIV5 viral isolate, SER (Fig. 4A). SER is a
porcine isolate of PIV5 that grows to titers equivalent to W3A
but, unlike W3A, does not form syncytia in infected cells
(Bissonnette et al., 2006; Seth et al., 2003; Tong et al., 2002).
The F protein of SER has nine residue differences as compared
to W3A F and a 22 amino acid extension to its cytoplasmic tail
(Tong et al., 2002). Previous studies suggest that this extended
tail forms a structure that inhibits fusion (Seth et al., 2003;
Waning et al., 2004). One of the SER mutations is a serine to
proline mutation at residue 443. In previous studies, introducing
an S443P mutation into W3A F caused a hyperfusogenic
phenotype with cell–cell fusion occurring at 22 °C (Paterson et
al., 2000). It is thought that S443P destabilizes the pre-fusion
form of the F protein, rendering F activated at lowered
temperature (Paterson et al., 2000; Yin et al., 2006).
In addition to SER, W3Avirus fusion was compared to PIV5
mutants containing F mutations in the W3A background (Fig.
4A). The 22 amino acid tail extension of SER was added to the
W3A F protein, and a virus carrying this protein (rSV5 F551)
was generated by reverse genetics (Waning et al., 2004). W3A
virus carrying the hyperfusogenic S443P mutation was also
generated (rSV5 S443P), as well as W3A virus carrying both
S443P and the SER tail extension (rSV5 F551-S443P). Based
on fusion studies in cells transfected with these F constructs
(Waning et al., 2004), we expected to see reduced levels of
fusion for SER and rSV5 F551, increased fusion for rSV5
S443P, and intermediate fusion for rSV5 F551-S443P.
All of the purified virus preparations showed similar levels
of purity when analyzed by silver stain (Fig. 4B and data not
shown). When R18 virus–cell fusion assay was performed
with the mutant viruses, using BHK cells or RBC ghosts as
target cells, it was found that W3A and SER fusion levels
were similar (Figs. 4C, D), whereas rSV5 F551 fusion was
reduced. As found for W3A, SER and rSV5 F551 fusion was
eliminated by treatment of cells with neuraminidase (Figs.
4C, D). Fusion of SER and rSV5 F551 with both BHK cells
and RBC ghosts was temperature-dependent, with both the
extent and rate of fusion increasing at elevated temperatures
(Fig. 5).
No fusion with RBC ghosts was observed for rSV5 S443P or
rSV5 F551-S443P viruses (data not shown). Although the HA
titers for these viruses were comparable to the others, their
infectivity titers were reduced by ∼1 log. One explanation for
the lack of detectable fusion for the rSV5 S443P and rSV5
Fig. 5. Temperature dependence of SER and rSV5 F551 fusion with BHK cells. Fusion of R18-labeled SER (A, C) or rSV5 F551 (B, D) with BHK cells (A, B) or RBC
ghosts (C, D) was monitored as in Fig. 2 or 3 with the PBS in the cuvette held at the indicated temperatures during fusion. Fusion with neuraminidase-treated RBC
ghosts was monitored as a negative control.
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partially inactivated due to their temperature lability during the
course of virus growth and thus these virion preparations were
fusion inactive.
Discussion
Unlike most low pH-dependent viruses for which fusion is
triggered by acidic pH and a single protein is responsible for both
receptor binding and membrane fusion, paramyxovirus fusion
occurs at neutral pH and is triggered by an interaction of HNwith
F protein. When influenza virus enters cells by endocytosis, the
time course of fusion is slow, due to the requirement of
endocytosis and acidification of endosomes (Lakadamyali et al.,
2003; Nunes-Correia et al., 2002; Stegmann et al., 1987).
However, when fusion of influenza virus is triggered by the
addition of exogenous acid, fusion with target membranes
reaches a maximum plateau within 1–5min (Chu andWhittaker,
2004; Danieli et al., 1996; Mittal et al., 2002; Ramalho-Santos
and Pedroso De Lima, 1999; Sun andWhittaker, 2003; Takeda et
al., 2003). Other studies demonstrate that low pH-triggered
fusion of viruses such as Sindbis virus, Semliki Forest virus, and
tick-borne encephalitis virus progresses even more rapidly,
reaching completion within seconds (Corver et al., 2000; Smit et
al., 1999;Waarts et al., 2002). The kinetics of PIV5 fusion in thisstudy were more similar to the former, occurring over several
minutes.
Previous studies report widely disparate rates of fusion for
paramyxoviruses. For example, the time required for Sendai
virus fusion to approach a maximum varies from approximately
10 min (Hoekstra and Klappe, 1986) to well over 16 h (Wharton
et al., 2000), a time frame that exceeds the replication time of
the virus. Nevertheless, no studies show paramyxovirus fusion
occurring within seconds as has been reported for some low pH-
triggered viruses (Corver et al., 2000; Smit et al., 1999; Waarts
et al., 2002). Thus, the slow fusion rates measured for PIV5 in
this study generally agree with previous rates measured for
Sendai virus (Hoekstra and Klappe, 1986; Ludwig et al., 2003;
Ohki et al., 1998). Both the pyrene and R18 fusion assays used
in this study demonstrate viral fusion within a biologically
relevant time frame. The relatively slow fusion kinetics indicate
that, even though the virus samples were adsorbed to the target
cells at 4 °C, fusion of the virus population did not proceed
immediately in a synchronous wave upon heating. The slow
kinetics may be due to a slow conversion of F proteins from the
pre-fusion to the post-fusion form or to a slow (or stochastic)
triggering of the F proteins by HN.
Just as a reduction in pH increases the rate of fusion of low
pH-activated viruses (Mittal et al., 2002), an increase in
temperature increased both the rate and extent of fusion for the
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protein exists in a metastable form and increasing the
temperature reduces the energy threshold required to trigger F
into a fusogenic form. The temperature dependence of PIV5
fusion has been shown in cell–cell fusion assays, and specific
mutations in F can increase or decrease the activation energy
threshold (Paterson et al., 2000; Russell et al., 2004; Russell et
al., 2003). The temperature dependence of virus fusion has also
been demonstrated for other viruses, including both pH-
dependent and pH-independent viruses such as influenza
virus, Rous sarcoma virus, and Newcastle disease virus (Carr
et al., 1997; Gilbert et al., 1990; San Roman et al., 1999).
Correspondingly, exposing PIV5 to high temperature (65 °C) in
the absence of target membrane inactivated virus fusion (Fig.
1E) and heat treatment was observed to inhibit fusion more
effectively than F1a antibody or C1 peptide. Most likely, the
high temperature treatment prevents fusion by triggering F into a
post-fusion conformation prior to contact with the target cells.
Alternatively, elevated temperature may alter the virus particles
in another manner to prevent fusion.
The overall molecular mechanism of F protein-mediated
fusion is thought to be the same for virus–cell fusion and cell–
cell fusion. Both fusion events are temperature-dependent,
inhibited by C1 peptide, and blocked by the neutralizing MAb
F1a (Figs. 1B, C, D) (Paterson et al., 2000; Randall et al., 1987;
Russell et al., 2001). The level of C1 peptide required to inhibit
virus–cell fusion exceeded the IC50 for C1 inhibition of cell–cell
fusion (35 nM; Russell et al., 2001), even after taking into
account the fact that the peptide concentration was reduced 30-
fold upon injection into the cuvette. This may reflect differences
in the concentration of F protein or the accessibility of the C1
binding site in the context of a virion compared to a transfected
cell.
We expected that both the SER and rSV5 F551 virus strains
would have slower kinetics of fusion than W3A as these viruses
demonstrate reduced fusion in cell–cell fusion assays (Bissonn-
ette et al., 2006; Seth et al., 2003; Tong and Compans, 1999;
Waning et al., 2004). However, it was observed that, whereas
rSV5 F551 had a slower rate and extent of fusion, SER andW3A
fused at similar levels (Figs. 4C, D). In cell–cell fusion assays,
the extended cytoplasmic tails of the SER and F551 F proteins
inhibit fusion, possibly by forming a cytoplasmic structure that
slows the conformational changes required for fusion (Seth et
al., 2003; Waning et al., 2004). In the context of virus–cell
fusion, this inhibition remains for rSV5 F551, but not for SER.
Presumably, the inhibition is overcome by eight residue changes
within the SER F protein (Fig. 4A).
The location of the residue changes between W3A and SER
in the pre-fusion structure of the PIV5 F protein (Yin et al.,
2006) suggests a scenario by which the SER mutations
overcome the inhibition imposed by an extended cytoplasmic
tail. With the exception of M370, the individual mutation of any
one of these residues to the corresponding W3A residue was
reported to restore syncytium formation in transfected cells
(Seth et al., 2004). Residues 132 and 149 lie within HRA, a
region that undergoes a drastic conformational change during
fusion to reposition the fusion peptide toward the targetmembrane (Yin et al., 2005, 2006). These two residues flank
HRA helix 2, with residue 132 at a bend that connects helix 1
and helix 2 and residue 149 within a loop that connects helix 2
to beta strand 1 (Yin et al., 2006). Mutation of these residues
may affect the rate at which the HRA refolds into a single long
helix. Previous work demonstrated that a mutation at residue
132 confers HN independence to cell–cell fusion of another
PIV5 mutant (Ito et al., 2000). Residues 438 and 443 lie within
the HRB linker region at the base of the head of the pre-fusion
molecule. Mutations at these residues may affect the efficiency
at which HRB refolds upon fusion to form a 6-helix bundle with
HRA. In this regard, previous work has shown that the S443P
mutation in a W3A background results in a hyperfusogenic
phenotype in cell–cell fusion assays (Paterson et al., 2000;
Russell et al., 2003).
Analysis of SER fusion in this study demonstrates a
difference between cell–cell fusion and virus–cell fusion.
Although BHK cells infected with SER do not form syncytia
and cells transfected with SER F and HN have greatly reduced
syncytium formation compared to W3A (Bissonnette et al.,
2006; Seth et al., 2003; Tong et al., 2002), SER virus fusion with
BHK cells or RBC ghosts occurred as rapidly as that of W3A
(Figs. 4C, D). This may explain why SER and W3A grow to
equivalent titers (Bissonnette et al., 2006). Thus, while the
extended cytoplasmic tail of SER F inhibits cell–cell fusion,
virus–cell fusion for SER appears to be unaffected by the long
tail.
Cell–cell fusion differs from virus–cell fusion in that the
potential region of contact between membranes is larger,
cytoskeletal rearrangements on both sides of the fusion reaction
may affect the rate and extent of fusion, the densities of F andHN
in the membrane may be different, and the lipid composition of
the membranes may differ from the virion membrane. PIV5
fusion most likely requires the cooperation of multiple trimers of
F protein (Dutch et al., 1998), and thus the concentration of F in
the membrane may affect the extent of fusion. Monitoring the
fusion of PIV5 viruses with cells in real time revealed both
similarities and differences between the cell–cell and virus–cell
fusion reactions. The fluorescence-based virus–cell fusion
assays developed in this study complement the various cell–
cell fusion assays currently employed to examine the mechanism
of PIV5 fusion.Materials and methods
Antibodies and C1 peptide
Monoclonal antibody (MAb) F1a (Randall et al., 1987)
specific for PIV5 F and MAb 14C2 (Zebedee and Lamb, 1988)
specific for influenza virus M2 protein were used, and their
IgGs were purified using AffinityPak Protein A columns
(Pierce). The concentration of IgG preparations was determined
by OD280. Polyclonal antibodies (PAb) vacF and vacHN
(Paterson et al., 1987) were raised against vaccinia-expressed
PIV5 F and PIV5 HN respectively. The C1 peptide contains the
amino acid residues of the W3A F protein HRB and extended
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described previously (Joshi et al., 1998).
Cells and viruses
Madin-Darby bovine kidney (MDBK), CV-1, and baby
hamster kidney-21F (BHK) cells were maintained as described
previously (Paterson and Lamb, 1993; Russell et al., 2003).
Human red blood cells (RBC) were obtained with the approval
of the Northwestern University Institutional Review Board. To
prepare human erythrocyte ghosts, RBCs were washed extens-
ively with PBS (50 mM phosphate buffer, pH 7.0, 150 mM
NaCl) followed by PBS+ (PBS supplemented with 500 μM
Mg2Cl and 900 μM CaCl2) at pH 8. To release hemoglobin,
RBCs were washed 3 times with 5 mM Na2HPO4 at pH 8,
pelleted at 17,000×g for 10 min, resuspended in PBS+, pelleted
again, and resuspended in PBS+. After 30 min at 37 °C, RBC
ghosts were diluted to 2.5 mg/mL protein and stored at 4 °C. For
neuraminidase (NA)-treated BHK cells or RBC ghosts, NA
(Sigma Aldrich) was added at 100 mU/mL for 1 h at 37 °C.
PIV5 isolates W3A and SER (kindly provided by Dr. Richard
W. Compans, Emory University, Atlanta, GA) and PIV5 W3A
with an F protein containing mutations (rSV5 F551, rSV5
S443P, and rSV5 F551-S443P) (Waning et al., 2004) were
purified from supernatants of MDBK cells infected at 0.2 pfu/
cell for 4 days. To incorporate pyrene biosynthetically into
virions, subconfluent MDBK monolayers were infected with
W3A at 4 pfu/cell. After 1.5 h at 37 °C, 1-pyrenehexadecanoic
acid (15 μg/mL) (Invitrogen) was added to the medium.
Supernatants were harvested after 48 h at 37 °C. Influenza
strain A/Udorn/72 was purified from the allantoic fluid of
infected embryonated chicken eggs. For purification, infected
cell supernatants were clarified at 1600×g for 15 min at 4 °C.
Virus was pelleted at 118,000×g for 1 h, resuspended in NTE
(100 mM NaCl, 10 mM Tris hydrochloride pH 7.4, 1 mM
EDTA), and banded through 20–60% sucrose gradients for 75
min at 77,000×g. Virus bands were collected, pelleted at
118,000×g for 1 h, and resuspended in TE (10 mM Tris
hydrochloride pH 7.4, 1 mM EDTA). Protein concentrations of
the purified virus stocks and RBC ghosts were determined using
BCA Protein Assay Reagent (Pierce).
Immunostain plaque assay and HA titer
Confluent CV-1 cell monolayers were infected with serial
dilutions of virus preparations in DMEM supplemented with
1% bovine serum albumin (BSA). After 1.5 h at 37 °C, infected
cells were overlaid with DMEM containing 1% agarose and 2%
FCS. Cells were incubated for 4 days at 37 °C and fixed with
1% glutaraldehyde in PBS+ for 2 h. Blocking solution (3% egg
albumin in PBS) was added to the cells for 30 min followed by
PAb sera vacF and vacHN for 1 h at a 1:100 dilution in blocking
solution. Monolayers were washed 4 times with PBS, and HRP-
conjugated goat-anti-rabbit secondary Ab (Jackson) was added
for 1 h at a 1:500 dilution in blocking solution. Cells were
washed again, and plaques were visualized by adding DAB
substrate (Pierce).To determine HA titer, virus preparations were serially
diluted in 96 well U-bottom plates with PBS+ (100 μL/well).
After the addition of 100 μL/well 0.5% hematocrit chicken
RBC, plates were incubated at 4 °C for 2 h. The HA titer was
recorded as the reciprocal of the highest dilution at which
agglutination occurred.
Pyrene virus–cell fusion assay
BHK cells were released from plates using 530 μM EDTA in
PBS. Cells were pelleted and resuspended in PBS at 3×107
cells/mL. Purified pyrene-labeled W3Awas added to BHK cells
in 100 μL PBS at 3 pfu/cell for 30 min on ice. The virus–cell
mixtures were then injected into cuvettes holding 3 mL PBS+
pre-warmed to 37 °C. Fluorescence emission from 351 to
510 nm was monitored using a spectrofluorimeter (AB2) with
continuous scanning at 5 nm/s and 343 nm excitation. To
measure fusion kinetics, pyrene monomer fluorescence was
monitored continuously with 1 s time resolution at 343 and
396 nm of excitation and emission, respectively. Temperature
was controlled using a waterbath circulation system and
constant stirring. To determine the maximum level of monomer
fluorescence (Ft), Triton X-100 was injected at 1000 s at a final
concentration of 1%. To normalize the data, readings were
expressed as a percentage of this maximum with initial readings
subtracted, i.e. 100 (F−F0) / (Ft−F0), where F0 and F are the
fluorescence at time zero and at a given time point. When noted,
MAb or peptide was added to the virus on ice for 30 min prior to
binding cells.
R18 virus–cell fusion assays
Purified virus (20 μg per sample) was diluted to 240 μg/mL
in PBS+ and mixed with the lipid probe octadecyl rhodamine
B (R18; Molecular Probes) at 4 μg/mL. After 30 min at room
temperature, virus was pelleted through 20% sucrose at
66,000×g for 1 h and resuspended in PBS+ (40 μL per
sample). For each sample, 40 μL of virus was added to 80 μL
of BHK cells (∼3×107 cells/mL) or 40 μL of RBC ghosts on
ice for 30 min. The virus–cell mixtures were injected into
cuvettes holding 3 mL PBS+ pre-warmed to 37 °C. Fluore-
scence dequenching was monitored continuously as above at
560 and 590 nm of excitation and emission, respectively. A
570 nm filter was placed in the emission pathway to reduce
scattering. Temperature was controlled as above. To determine
the maximum level of dequenching, Triton X-100 was
injected at 1000 or 200 s at a final concentration of 1%. To
normalize the data, readings were expressed as a percentage
of this maximum. F0 was not subtracted from samples with
RBC ghosts due to spikes in the readings. When noted, MAb
was added to the virus on ice for 30 min prior to binding
cells.
SDS-PAGE and silver stain
Ten micrograms of each purified virus sample was diluted in
loading buffer (0.5 mM Tris pH 6.8, 5% SDS, 7.5% DTT, 50%
211S.A. Connolly, R.A. Lamb / Virology 355 (2006) 203–212glycerol) and boiled for 5 min. Proteins were analyzed by SDS-
PAGE using a 10% acrylamide gel. Polypeptides were
visualized by silver staining.
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